Asston Pharmaceuticals has completed a preferential allotment of 24.1 lakh equity shares at Rs 115 per share, raising approximately Rs 27.7 crore. The move increases the company's total paid-up capital to Rs 10.92 crore, comprising 1.09 crore shares. While this bolsters the company's balance sheet for future growth, existing shareholders should factor in the resulting equity dilution. The shares were issued to 15 public investors, with Vijay Rathee and Vijaylaxmi Infra Projects emerging as the primary allottees.
Asston Pharmaceuticals Allots 24.1 Lakh Shares in Preferential Issue
Total funds raised: Rs 27.72 crore | New share price: Rs 115 per share
Reader Takeaway: The capital infusion strengthens liquidity for strategic initiatives but results in immediate equity dilution for existing shareholders.
What just happened
Asston Pharmaceuticals Limited has officially executed a preferential allotment of 24,10,431 equity shares. The board approved the issuance at a price of Rs 115 per share, which includes a premium of Rs 105 over the Rs 10 face value. This transaction successfully concluded on September 5, 2026, with 15 investors from the public category participating in the round.
Why this matters
The allotment increases the company’s total paid-up equity share capital to Rs 10.92 crore, divided into 1,09,22,791 shares. For investors, this represents a significant capital injection intended to fuel the company's operational or strategic objectives. However, because the total number of outstanding shares has grown, existing shareholders face a proportional dilution of their current ownership interest.
The allottees
The allotment was spread across 15 investors. The most significant allocations were awarded to:
- Vijay Rathee: 13,17,391 shares
- Vijaylaxmi Infra Projects Private Limited: 7,82,608 shares
The remaining shares were distributed among 13 other investors, including entities like Shreevardhan Nitin Tupe, who received 86,956 shares, and others such as Swapneel Pradeep Rane and Jayaram Chitturi.
What changes now
The newly issued shares are fully rank-pari passu with the company's existing equity, meaning these shares carry equal voting and dividend rights. Market participants should monitor upcoming quarterly disclosures to assess how these funds are deployed and whether the capital is being directed toward expansion or debt reduction.
What to track next
Shareholders should watch for future regulatory filings regarding the specific utilization of these funds. Additionally, monitor the stock's price discovery as the market absorbs the supply of new equity.